stockrow
Saturday 7 November 2026
Export ACRS’s income statement to Excel — free account
Aclaris Therapeutics, Inc.
ACRS Healthcare Biotechnology
Aclaris Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $7.8 million, down 58.2% from fiscal 2024.
- Revenue
- −55.1%
- EPS
- 0.00%
- Free cash flow
- −119.9%
Quarter to September 2026, against a year earlier
3.88
0.27
+7.48%
Follow ACRS
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 5 Nov | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(50.20%) | (48.42%) | (59.10%) | (55.51%) | |
Piotroski F-Score |
3 | 3 | 4 | — | |
| (34.10%) | (35.11%) | (41.07%) | (40.66%) | ||
ROIC |
(387.11%) | (131.57%) | (163.35%) | (107.72%) | |
Return on Tangible Assets |
(94.87%) | (83.32%) | (107.91%) | (79.93%) | |
Average Days of Receivables |
259.55 | 210.00 | 275.74 | 0.00 | |
Free Cash Flow per Share |
(0.39) | (0.41) | (0.44) | (0.50) | |
Free Cash Flow |
(47.22) | (52.29) | (62.18) | (75.31) | |
Capital Expenditures |
(0.11) | (0.08) | (0.12) | (0.11) | |
| Other line items | |||||
Cash ROIC |
(24.36%) | (20.99%) | (28.77%) | (26.79%) | |
Accounts Receivable Turnover |
0.87 | 3.30 | 2.57 | 0.00 | |
Accounts Payable Turnover |
0.82 | 0.72 | 0.59 | 0.00 | |
Inventory Turnover |
0.00 | 0.00 | 0.00 | — | |
Average Days of Payables |
659.35 | 711.60 | 791.08 | 0.00 | |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | — | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
672.69% | 677.88% | 770.59% | 1,036.92% | |
Selling, General and Administrative Expense of Revenue |
280.76% | 269.82% | 282.74% | 381.27% | |
Share Based Compensation of Revenue |
158.24% | 143.98% | 141.82% | 184.58% | |
Operating CF/Net income |
0.73 | 0.75 | 0.82 | 0.94 | |
Depreciation/Fixed assets |
0.60 | 0.57 | 0.63 | 0.66 | |
Capex/Depreciation |
(0.24) | (0.19) | (0.28) | (0.26) | |
Revenue per Share |
0.06 | 0.07 | 0.06 | 0.04 | |
Operating CF per Share |
(0.38) | (0.41) | (0.43) | (0.50) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.01 | 0.01 | 0.02 |
Columns are period end dates · fundamentals updated 5 Nov 2026